Anbalagan (Anbu) Jaganathan has over 12 years of research experience in biology, with a strong focus on epigenetic mechanisms underlying various human diseases. He earned his Ph.D. from the University of Madras, India, where he investigated endocrine system dysfunction and hormone/receptor signaling in male reproductive health. During his postdoctoral training at the Icahn School of Medicine at Mount Sinai and Cold Spring Harbor Laboratory in New York, Anbu explored the roles of key epigenetic regulators—BET proteins, MYST1, and Chromodomain Helicase DNA-binding Protein 5 (Chd5)—in inflammation and cancer. His research uncovered critical interactions between MYST1, the androgen receptor (AR), and NF-κB that drive the progression of prostate cancer. He also demonstrated that BET family members Brd2 and Brd4 have distinct genomic functions in regulating gene transcription during Th17 cell differentiation, and that targeting BET proteins with small molecules can suppress inflammatory Th17 cells responses. He later transitioned into the biotech industry, where he worked as a Senior Scientist at Simisco leading efforts in the discovery and development of targeted therapeutics using synthetic antibody platforms. His responsibilities included antibody generation, detailed characterization, and execution of functional cell-based assays to support therapeutic validation. Currently, he serves as a Principal Scientist at Aarvik Therapeutics, contributing to the advancement of next-generation drugs using antibody drug conjugation.